Deutsche Bank Analysts Give Novartis (VTX:NOVN) a CHF 90 Price Target

Novartis (VTX:NOVN) received a CHF 90 price objective from analysts at Deutsche Bank in a report released on Monday, January 15th. The firm currently has a “neutral” rating on the stock. Deutsche Bank’s price target would suggest a potential upside of 7.81% from the company’s previous close.

Other analysts have also issued reports about the company. Societe Generale set a CHF 95 price target on Novartis and gave the stock a “buy” rating in a research note on Wednesday, October 25th. JPMorgan Chase & Co. set a CHF 75 price target on Novartis and gave the stock a “neutral” rating in a research note on Wednesday, October 25th. set a CHF 90 price target on Novartis and gave the stock a “buy” rating in a research note on Monday, October 30th. Barclays set a CHF 75 price target on Novartis and gave the stock a “sell” rating in a research note on Wednesday, October 25th. Finally, UBS Group set a CHF 78 price target on Novartis and gave the stock a “neutral” rating in a research note on Monday, October 30th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of CHF 87.38.

Shares of Novartis (NOVN) opened at CHF 83.48 on Monday. Novartis has a 1-year low of CHF 69.50 and a 1-year high of CHF 85.40. The company has a market capitalization of $219,390.00 and a P/E ratio of 30.80.

ILLEGAL ACTIVITY NOTICE: “Deutsche Bank Analysts Give Novartis (VTX:NOVN) a CHF 90 Price Target” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/01/22/novartis-novn-given-a-chf-90-price-target-at-deutsche-bank.html.

About Novartis

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply